Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Group B Streptococcus type Ia capsular polysaccharide (GBS Ia CPS)
- Target
- GBS Ia CPS
- Molecular classification
- Other (Bacterial capsular polysaccharide)
01
Overview
The Group B Streptococcus type Ia capsular polysaccharide is a high-molecular-weight, surface-exposed carbohydrate composed of a repeating pentasaccharide unit that includes glucose, galactose, N-acetylglucosamine, and sialic acid (N-acetylneuraminic acid). The immunodominant side chain terminates in α-(2→3)-linked sialic acid, a motif shared among several GBS serotypes and critical for evasion of complement and phagocytosis. This capsule is a key virulence factor, protecting the bacteria from host immunity. Its type-specific structure enables precise serotyping and is the primary antigenic target for both natural and vaccine-induced immunity. Capsular polysaccharides from various GBS serotypes, including type Ia, are under development as part of conjugate vaccines to prevent neonatal and maternal GBS infections.
- Other names
- GBS type Ia capsular polysaccharideStreptococcus agalactiae serotype Ia CPSGBS Ia CPS
02
Mechanism of action
Vaccines: Induce production of capsular polysaccharide–specific antibodies that opsonize and promote phagocytic killing of GBS.
03
Biological functions
Immune evasion (inhibits complement-mediated killing and phagocytosis)Antigenic determinant for serotypingVirulence factor
04
Disease associations
Infection (key virulence determinant in *Streptococcus agalactiae* infections, especially in neonatal sepsis and meningitis)
05
Safety considerations
Polysaccharide vaccines may have limited immunogenicity in very young infants unless conjugated to a carrier proteinPotential antigenic cross-reactivity with host structures is a theoretical concern for all polysaccharide-based vaccines, though not reported for GBS Ia
06
Interacting drugs
Capsular polysaccharide-protein conjugate vaccines (e.g., GBS vaccines in development)
07
Biomarkers
Presence of anti-GBS Ia CPS antibodies as a marker of immunogenicity after vaccinationDetection of capsular polysaccharide as a diagnostic biomarker for serotype identification
Beyond the preview
Go deeper on Group B Streptococcus type Ia capsular polysaccharide (GBS Ia CPS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group B Streptococcus type Ia capsular polysaccharide (GBS Ia CPS).